Skip to main content
. 2018 Sep 25;19(10):2902. doi: 10.3390/ijms19102902

Figure 1.

Figure 1

Chest and abdominal computed tomography (CT) in the present case. Chest CT of the patient with ALK-positive NSCLC at diagnosis (A), after 1 month (B), and after 11 months (C) of crizotinib therapy. Abdominal CT of the patient before therapy with crizotinib (D), 11 months after crizotinib therapy (E), 13 months (F) after crizotinib therapy, and after stopping the drug (G). NSCLC: non–small cell lung cancer; ALK: anaplastic lymphoma kinase.